Code Moment | Sirius Pharma Closes Nearly $40 Million Series B+ Round, Existing Shareholder Source Code Capital Continues to Double Down
Sirius Pharma announced the completion of a nearly $40 million Series B+ funding round, with existing shareholder Source Code Capital continuing to increase its stake.









